143 related articles for article (PubMed ID: 34979828)
1. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.
Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N
Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
Yomo S; Oda K; Oguchi K
J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
[TBL] [Abstract][Full Text] [Related]
4. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL
J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086
[TBL] [Abstract][Full Text] [Related]
5. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
[TBL] [Abstract][Full Text] [Related]
6. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J
J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
Shepard MJ; Xu Z; Donahue J; Eluvathingal Muttikkal TJ; Cordeiro D; Hansen L; Mohammed N; Gentzler RD; Larner J; Fadul CE; Sheehan JP
J Neurosurg; 2019 Jul; 133(3):685-692. PubMed ID: 31349225
[TBL] [Abstract][Full Text] [Related]
8. The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations.
Mehkri Y; Windermere SA; Still MEH; Yan SC; Goutnik M; Melnick K; Doonan B; Ghiaseddin AP; Rahman M
World Neurosurg; 2024 Jan; 181():e133-e153. PubMed ID: 37739175
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores.
Yomo S; Oda K; Oguchi K
J Neurosurg; 2023 Jun; 138(6):1591-1599. PubMed ID: 36308485
[TBL] [Abstract][Full Text] [Related]
10. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
11. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients.
Lehrer EJ; Ahluwalia MS; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Jones BM; Green S; Sheehan JP; Trifiletti DM
J Neurosurg; 2023 May; 138(5):1178-1187. PubMed ID: 36115055
[TBL] [Abstract][Full Text] [Related]
12. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis.
Kotecha R; Kim JM; Miller JA; Juloori A; Chao ST; Murphy ES; Peereboom DM; Mohammadi AM; Barnett GH; Vogelbaum MA; Angelov L; Suh JH; Ahluwalia MS
Neuro Oncol; 2019 Aug; 21(8):1060-1068. PubMed ID: 30796838
[TBL] [Abstract][Full Text] [Related]
13. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes.
Shanker MD; Garimall S; Gatt N; Foley H; Crowley S; Le Cornu E; Muscat K; Soon W; Atkinson V; Xu W; Watkins T; Huo M; Foote MC; Pinkham MB
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):536-545. PubMed ID: 35343063
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.
Dohm AE; Tang JD; Mills MN; Liveringhouse CL; Sandoval ML; Perez BA; Robinson TJ; Creelan BC; Gray JE; Etame AB; Vogelbaum MA; Forsyth P; Yu HM; Oliver DE; Ahmed KA
J Neurosurg; 2023 Jun; 138(6):1600-1607. PubMed ID: 36681988
[TBL] [Abstract][Full Text] [Related]
18. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Aizer AA; Rahman R; Guenette JP; Huang RY
Eur Radiol; 2021 Jun; 31(6):4114-4129. PubMed ID: 33241519
[TBL] [Abstract][Full Text] [Related]
20. Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study.
Lehrer EJ; Gurewitz J; Bernstein K; Patel D; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Malouff TD; Ruiz-Garcia H; Patel S; Bonney PA; Hwang L; Yu C; Zada G; Mathieu D; Trudel C; Prasad RN; Palmer JD; Jones BM; Sharma S; Fakhoury KR; Rusthoven CG; Deibert CP; Picozzi P; Franzini A; Attuati L; Lee CC; Yang HC; Ahluwalia MS; Sheehan JP; Trifiletti DM
Cancer; 2022 Apr; 128(7):1429-1438. PubMed ID: 35077586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
